Aldeyra Therapeutics ($ALDX) Receives FDA Complete Response Letter for Reproxalap
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the...
Nasus Pharma ($NSRX) Reports Positive Phase 2 Results for NS002 Intranasal Epinephrine
Nasus Pharma Ltd. (NYSE: NSRX) reported positive initial results from its Phase 2 clinical trial of NS002, an investigational intranasal epinephrine powder for treating...